Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

High-Grade Urothelial Carcinoma of Bladder Transforming to Micropapillary Variant on Follow-Up.

Kumari N, Jha A, Vasudeva P, Agrawal U.

Iran J Med Sci. 2017 May;42(3):318-321.

2.

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.

Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirström K.

Biomark Res. 2017 Mar 14;5:10. doi: 10.1186/s40364-017-0090-y. eCollection 2017.

3.

Epithelial plasticity in urothelial carcinoma: Current advancements and future challenges.

Garg M.

World J Stem Cells. 2016 Aug 26;8(8):260-7. doi: 10.4252/wjsc.v8.i8.260. Review.

4.

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ.

Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May.

5.

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience.

Bazzi WM, Kopp RP, Donahue TF, Bernstein M, Russo P, Bochner BH, Donat SM, Dalbagni G, Herr HW.

Int Sch Res Notices. 2014 Nov 13;2014:702653. doi: 10.1155/2014/702653. eCollection 2014.

6.

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.

Kim B, Kim G, Song B, Lee C, Park JH, Moon KC.

Dis Markers. 2016;2016:8463731. doi: 10.1155/2016/8463731. Epub 2016 Mar 10.

7.

The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer.

Gofrit ON, Yutkin V, Shapiro A, Pizov G, Zorn KC, Hidas G, Gielchinsky I, Duvdevani M, Landau EH, Pode D.

Front Oncol. 2016 Mar 15;6:43. doi: 10.3389/fonc.2016.00043. eCollection 2016.

8.

Cutaneous invasion from sarcomatoid urothelial carcinoma: clinical and dermatopathologic features.

Bernardes Filho F, de Melo AS, Pires AR, Lupi O, das Neves DG, da Cruz MF, Kac BK.

An Bras Dermatol. 2016 Jan-Feb;91(1):73-9. doi: 10.1590/abd1806-4841.20164081.

9.

Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression.

Ball MW, Bezerra SM, Chaux A, Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Bivalacqua TJ, Netto GJ, Burnett AL.

Urology. 2016 Jun;92:51-6. doi: 10.1016/j.urology.2016.02.006. Epub 2016 Feb 18.

10.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter VE, Taylor BS, Solit DB.

Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.

11.

Bladder preserving approach for liposarcomatoid variant of transitional urothelial carcinoma.

Singh SK, Mittal A, Mukhopadhyay A, Kakkar N, Chatterjee D.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E886-9. doi: 10.5489/cuaj.3167. Epub 2015 Dec 14.

13.
14.

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G.

PLoS One. 2015 Jul 31;10(7):e0131245. doi: 10.1371/journal.pone.0131245. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0143990. Hoque, Mohammad [corrected to Hoque, Mohammad Obaidul].

15.
16.

Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder.

Kim HS, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH.

Sci Rep. 2015 May 11;5:9626. doi: 10.1038/srep09626.

17.

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.

Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, Seiler R, Thalmann GN, Fleischmann A.

Virchows Arch. 2015 Jun;466(6):703-10. doi: 10.1007/s00428-015-1729-4. Epub 2015 Mar 26.

18.

Expression of RCAS1 correlates with urothelial bladder cancer malignancy.

Jóźwicki W, Brożyna AA, Siekiera J, Slominski AT.

Int J Mol Sci. 2015 Feb 10;16(2):3783-803. doi: 10.3390/ijms16023783.

19.

Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP, Al-Ahmadie HA, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, Cheville JC, Kristiansen G, Cote RJ, Delahunt B, Eble JN, Genega EM, Gulmann C, Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, Netto GJ, Oliva E, Rao P, Ro JY, Srigley JR, Tickoo SK, Tsuzuki T, Umar SA, Van der Kwast T, Young RH, Soloway MS.

Mod Pathol. 2015 May;28(5):612-30. doi: 10.1038/modpathol.2014.158. Epub 2014 Nov 21. Review.

20.

Lymphoepithelioma-like carcinoma of the urinary bladder: a case report and review of the literature.

Yoshino T, Ohara S, Moriyama H.

BMC Res Notes. 2014 Nov 4;7:779. doi: 10.1186/1756-0500-7-779. Review.

Supplemental Content

Support Center